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Abstract
Background: Errors occur frequently in the use of medicines. Pharmacists play a key role in error identification
and make appropriate interventions as they work with other healthcare professionals. These error recovery roles of
pharmacists contribute to patient safety. This study was to evaluate the clinical interventions made to drug-related
problems at a tertiary care setting.
Method: This involved a retrospective review of clinical intervention reports submitted by pharmacists working
over the period January 2011 to December 2013.
Results: The 24 pharmacists submitted 529 handwritten reports; of these, 448 reports had complete data. The most
frequently reported drugs with error were warfarin (9.5%), potassium chloride (6.0%) and potassium citrate (5.5%).
The pharmacists made 1019 clinical interventions and recommendations. The average intervention per report was
2.5 (S.D ± 0.67). The interventions and recommendations made were categorised as drug regimen change (76.1%),
monitoring required (13.0%), communication (5.4%), counselling required (5.0%) and adverse drug reporting (0.6%).
Majority (90.5%) of the recommendations and interventions made by pharmacists were accepted and implemented.
Monitoring-required based interventions were significantly more likely to be accepted (130 vs 38; p <0.0001).
Conclusion: Pharmacists played a role in drug error recovery and prevented medication errors from reaching
patients. These error mitigation efforts of pharmacists can serve as a priority in patient safety strategy.
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Background
A substantial proportion of hospitalised patients experi-
ence medication-related harm that is preventable [1].
Drug errors have been estimated to account for over a
quarter of causes of adverse drug events [2]. Strategies
to prevent such problems are being developed. One such
strategy is the structured review of patient medication
by pharmacists to identify patients with medication er-
rors that may lead to harm. The advantage is that the
complete clinical status of each patient is taken into ac-
count when identifying problems [3]. In a study, clinical
pharmacists performed better than the decision support
system in identifying drug–drug interactions clinical in-
terventions [4]. The authors realised that clinical
pharmacists looked at individual administration intervals
and drug sequence to determine the clinical relevance of
the interactions.
The Harvard Medical Practice Study analysed error re-
covery, i.e. the circumstances under which errors were
detected and corrected. The study acknowledged the im-
portant role pharmacists play in identifying and correct-
ing drug errors from reaching patients.
The Institute of Medicine’s report includes recom-
mendations for health systems to implement error
reporting reviews [5]. In the inpatient setting, clini-
cians have used various drug event reporting pro-
grams to better understand and prevent drug errors
[6, 7]. The interception of medication errors is thus
essential for improving patient safety. The aim of the
study was therefore to evaluate the clinical interven-
tions of hospital pharmacists.
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Methods
The study was a retrospective review of reports, which
had no names, nor personal information of patients. No
consent was taken from patients since they could not be
traced to any reports.
Study setting
The study took place at Korle Bu Teaching hospital which
is a 2000 bed tertiary teaching hospital located in the cap-
ital city of Ghana. At the time of the study, the hospital
had about 80 pharmacists. The main pharmacy services
provided in the hospital were dispensing, clinical, drug in-
formation, research and small scale manufacturing. There
were about 30 pharmacists who actively undertake clinical
duties across the various wards of the hospital.
Data collection
To evaluate the clinical interventions of pharmacists
working in the hospital, copies of reports for the period
January 2011–December 2013 were made and relevant
data extracted using a specially designed data collection
sheet. Pharmacists had previously identified drug errors
and manually reported the clinical interventions. The
pharmacist interventions accepted and the actions taken
were reported on the submitted manual reports. Phar-
macists had discovered drug errors during their normal
duties from review of patient medical records, laboratory
reports, interactions with other health care professionals,
patients, caregivers or family members.
Data analysis
The extracted clinical intervention data was entered into
and analysed using SPSS (Statistical Package for Social
Sciences) version 16 for Windows. Descriptive analysis
was performed on all the data to obtain the frequency of
clinical interventions, drug characteristics and pharmacist
characteristics. Aggregate data were tabulated and sum-
marized using frequency statistics such as count, range,
mean and standard deviation. Descriptive analyses of all
drug error types and related interventions were also tabu-
lated. Pharmacist Clinical intervention data were com-
pared between drug classifications, drug error types and
whether pharmacist interventions were accepted or not
using Chi square test dichotomous variables. Any p < 0.05
was considered as statistically significant.
Results
Study participants
The evaluation revealed that 24 pharmacists made
529 paper-based reports over the 3 years. Majority of
them were female (70.8%) and more than half had
less than 10 years experience (53.3%). The basic char-
acteristics of pharmacists who made the reports are
presented in Table 1.
Drug error reports
Of the 529 paper-based drug error reports, 448 con-
tained complete information and hence were included in
the study. Reasons for not including the 79 were no drug
name (n = 67), no reason for error (n = 6) and no recom-
mendation (n = 6). Drug errors were reported from all
the units of the hospital that pharmacists worked; sur-
gery (24%), medicine (22%), paediatric (21%), obstetrics
and gynaecology (17%) and others (16%). Pharmacists
discovered drug errors from review of patient medical
records (74%), from other health care professionals
(10%), laboratory reports (8%), patients (6%), caregivers
(1%), and other unspecified sources (3%). The frequently
occurring therapeutic drug categories with errors were
cardiovascular (44.4%), infections (22.8%), nutrition
(12.9%) and musculoskeletal (6.6%). Table 2 describes
the therapeutic drug categories and the degree of accept-
ance. The five most frequently reported classes of drugs
associated with drug errors were antibiotics (20.2%), an-
ticoagulants (19.9), iron supplement (16.3%), diuretics
(9.4%) and non-steroidal anti-inflammatory drugs (4.4%).
The most frequently reported drugs with error were
warfarin (9.5%), potassium chloride (6.0%) and potas-
sium citrate (5.5%). The drug error types identified were
categorised as prescribing, dispensing/implementing,
administering/patient receiving and monitoring (see
Table 3). Majority of reported drug errors were due to
prescribing (70.9%) and least due to dispensing/imple-
menting (2.0%). The most frequently reported drugs as-
sociated with prescribing errors included cardiovascular
(42.6%), anti-infectives (22.9), and nutritional agents
(10.5%). During dispensing or implementation, the fre-
quently reported drug errors were anti-infectives
(50.0%), endocrine (35.0%) and cardiovascular (15.0%).













MSc in clinical pharmacy 8 33.3
MSc Clinical Pharmacy (student) 3 12.5
BPharm 13 54.2
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The most frequently reported drug category associated
with administration or patient receiving included anti-
infectives (45.5%), cardiovascular (22.7%) and central
nervous system (15.2%). The common reasons pharma-
cists provided for drug errors included untreated indica-
tion (18.9%), wrong dose prescribed (12.5%), wrong drug
prescribed (11.4%), medicine interactions (10.7%) and
duplication of therapy (9.8%).
Clinical interventions
The twenty most frequently drugs occurring in inter-
vention reports and their potential risk are presented
in Table 4. The pharmacists made 1019 interventions
and recommendations in 448 handwritten reports.
The average intervention per report was 2.5, standard
deviation (±0.67), range (2–4), and mode (2). The in-
terventions and recommendations made have been
categorised as drug regimen change (76.1%), monitor-
ing required (13.0%), communication (5.4%), counsel-
ling required (5.0%) and adverse drug reporting
(0.6%). The intervention types have been summarised
in Table 5. Monitoring-required based interventions
were significantly more likely to be accepted (130 vs
38; p <0.0001). Drugs involving drug regimen adjust-
ment by pharmacists included potassium citrate (n =
56), enoxaparin (n = 54), warfarin (n = 42), diclofenac
Table 2 Therapeutic category of drugs with intervention reports
Drug category Indication Number of recommended interventions *p-value
Accepted Not accepted
Cardiovascular (n = 451[44.3%]) Anticoagulant 181 22 0.053
Diuretic 87 9 <0.001
Calcium channel blockers 16 8 <0.001
Beta blockers 20 2 0.037
ACE inhibitors 14 2 0.003
Statin 17 3 <0.001
Antiplatelet 15 1 0.001
Nitrates 4 0 0.061
Angiotensin receptor blockers 3 0 <0.001
Others 41 6 0.004
Infections (n = 231[22.7%]) Antibiotics 180 18 0.019
Antimalarials 26 0 0.009
Antivirals 5 0 0.101
Antifungal 2 0 0.023
Nutrition (129 [12.7%]) Iron supplement 106 13 0.037
Others 10 0 <0.001
Musculoskeletal (70 [6.9%]) NSAIDS 52 3 0.010
Systemic Corticosteroids 11 0 <0.001
Others 4 0 <0.001
Central Nervous System (51[5%]) Opiod analgesic 39 3 <0.001
Sedatives 6 0 <0.001
Antiepileptic 2 1 0.122
Gastro-Intestinal (50 [4.9%]) Proton pump inhibitor 27 3 0.027
Antacid 7 0 0.980
Laxative 5 0 0.001
Others 6 2 0.001
Endocrine (14 [1.4%]) Oral antidiabetics 9 1 0.076
Insulin 4 0 0.001
Respiratory (11 [1.1%]) Inhalational steroids 10 0 0.530
Antihistamine 1 0 0.890
Others (12 [1.2%]) 12 0 <0.001
*Cross tabulation (χ2 test) between accepted and not accepted interventions for each Indication and the rest
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(n = 40), and morphine (n = 37). Monitoring required in-
terventions were made for potassium chloride (n = 46),
frusemide (n = 22), warfarin (n = 20), gentamicin (n = 19)
and metolazone (n = 14). Drugs requiring counselling in-
cluded warfarin (n = 44), iron supplement (n = 12), inhaled
steroid (n = 6), insulin (n = 4), and lamivudine (n = 3).
Drugs involving communication between pharmacist and
other healthcare professionals included frusemide (n = 31),
diclofenac (n = 18), iron supplement (n = 16), warfarin
(n = 11) and antacid (n = 7). Majority (90.5%) of the
recommendations and interventions made by pharma-
cists were accepted by prescribers and other health-
care professionals (see Table 5). These interventions
were communicated via the following means: verbal
(76.4%), write in patient medical notes (16.3%), acted
upon by reporting pharmacist (6.1%), prepare formal
note (0.7%) and prescribe/procure for patient (0.5%).
Discussion
This part of the study evaluated the clinical intervention
reports submitted by pharmacists working in a tertiary
hospital. The pharmacists identified drug related prob-
lems in the management of patients and made interven-
tions to prevent these errors from reaching patients.
Twenty-four pharmacists made 1019 clinical interven-
tions in 448 handwritten reports. Majority of the inter-
ventions related to drug therapy changes. Though this
study evaluated handwritten reports, it is comparable to
evaluations done on electronic incident reports [8, 9].
The categories of drugs most often associated with
drug error reports were similar to those reported
from previous studies and included cardiovascular
agents [10, 11], anti-infectives [11, 12], and central ner-
vous system agents [10, 13], suggesting that future strat-
egies for reducing drug errors could target these agents.
This study also found challenges with the use of nutri-
tional supplements. Most of the challenges with nutri-
tional supplements had to do with untreated anaemia,
which physicians had overlooked. Iron deficiency anaemia
is a serious nutritional problem in developing countries
given its impact on increased mortality or serious morbid-
ity in patients [14].
The frequently reported drug was warfarin as found in
other studies [15]. The use of warfarin presents substan-
tial safety concerns for patients. Adverse events associ-
ated with warfarin therapy are common [16]. This will
require prevention strategies targeted at the prescribing
and monitoring stages of warfarin management.
Though this study concentrated on pharmacists
identifying inpatient drug errors as in other studies,
results are comparable with studies conducted in out-
patients [11, 17–20]. The drug errors assessed in this
study were reports from only pharmacists although physi-
cians [11, 21], nurses [22, 23] and others [24, 25] had
reported drug errors in other studies.
The most frequently reported drug errors found in our
study were drug regimen change and originated from
drug prescribing. This finding is consistent with findings
from other studies conducted in clinical centres [26],
tertiary [27], hospital inpatient [28] and ambulatory care
settings [11]. Inappropriate prescribing predicts the risk
of adverse drug events [29]. The most commonly re-
ported prescribing drug error was untreated indication.
This was followed by prescribing wrong dose as seen in
other studies [11, 30]. Children are particularly at risk of
wrong dose errors [31].
The top two most frequently reported drug type as-
sociated with prescribing, dispensing and administra-
tion errors were cardiovascular and anti-infective
agents. The most commonly reported dispensing error
was dispensing wrong drug. Previous studies have re-
ported dispensing wrong drugs in all types of
Table 3 Drug error types and reasons
Error type Reasons Number
Prescribing (n = 721) Untreated indications 174
Wrong dose prescribed 127
Wrong drug prescribed 116
Medicine interactions 93
Duplication of therapy 84
Contraindications 78
Side effects 50
Failure to stop order 44








receiving (n = 66)
Unavailability of drug 19
Wrong dose administered 16
Duplication 16
Failure to discontinue 7
Others 4
Wrong drug administered 3
Wrong dosage form 1
Monitoring (n = 212) Laboratory test omitted 91
Blood glucose not monitored 77





Culture and sensitivity omitted 14
BP not checked 11
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inpatient settings [25, 32–35]. Omission due to drug
unavailability was also a common error identified.
Drug unavailability is common and poses a major
challenge to healthcare systems in transitional and de-
veloping countries [36, 37]. In addition to drug
omissions, administering wrong drug followed by
duplication were common reported administration
errors. The most commonly reported monitoring
error was omitting relevant laboratory test. Monitor-
ing errors had been previously reported [11].
Table 4 Drugs most frequently occurring in intervention reports and their potential risk






Warfarin 97 (9.5) Bleeding 89 8
Slow K 61 (6.0) Electrolyte imbalance 56 5
Gentamicin 60 (5.9) Tinnitus 45 15
Potassium Citrate 56 (5.5) Electrolyte imbalance 41 15
Enoxaparin 55 (5.4) DVT 46 9
Diclofenac 43 (4.2) Gastrointestinal bleeding 40 3
Heparin 39 (3.8) Bleeding 34 5
Morphine 38 (3.7) Respiratory depression 35 3
Frusemide 37 (3.6) Electrolyte imbalance 29 8
Iron Supplement 37 (3.6) Anaemia 34 3
Clindamycin 27 (2.6) Diarrhoea 25 2
Metolazone 26 (2.6) Electrolyte imbalance 26 0
Omeprazole 24 (2.4) Gastrointestinal bleeding 21 3
Atenolol 20 (2) Heart block 19 1
Hydrochlorthiazide 18 (1.8) Electrolyte imbalance 18 0
Metronidazole 16 (1.6) Increased hospital cost 14 2
Rosuvastatin 15 (1.5) Cardiovascular event 15 0
Cefuroxime 13 (1.3) Severe diarrhoea 13 0
Ciprofloxacin 13 (1.3) Muscle weakness 13 0
Lisinopril 13 (1.3) Neonatal mortality 11 2
Table 5 Types of pharmacist clinical interventions and degree of acceptance
Intervention type Method Number of reports Acceptance
Yes, n (%) No, n (%)
Drug regimen change (n=775[76.1%]) Verbal 643 730 (94) 45 (6)
Write in medical notes 109
Acted on by pharmacist 20
Prescribe/procure for patient 3
Monitoring required (n = 132 [13%]) Verbal 82 130 (98) 2 (2)
Write in patient medical notes 49
Write formal note 1
Counselling required (n = 52 [5.1%]) Verbal 9 49 (94) 3 (6)
Acted on by pharmacist 42
Prescribe/procure for patient 1
Communication (n = 54[5.3%]) Verbal 45 50 (93) 4 (7)
Write in medical notes 8
Prescribe/procure for patient 1
Adverse drug reporting (n = 6 [0.6%]) Write formal note 6 6 (100) 0 (0)
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More than 90% of interventions and recommendations
by pharmacists were accepted and implemented. Over
70% of the interventions involved drug regimen change.
Studies have reported prescribing errors as a major con-
tributor to patient harm in hospitals [10, 26, 28, 29, 38].
Most (76%) of the interventions were communicated
verbally. This would require an operational collaborative
working relationship between pharmacists and other
healthcare professionals to enhance patient care [39].
Previous studies reported that pharmacists in a collab-
orative team in hospitals helped reduce adverse drug
events by 30–86% [19, 40–42]. Pharmacists’ close prox-
imity with physicians provides opportunity for timely
verbal communications on error interceptions. Some of
the potential risk prevented by pharmacists included
bleeding, anaemia, nephrotoxicity, electrolyte imbalance,
severe diarrhoea etc.
Moreover, other interventions by pharmacists in this
study related to patient counselling. It has been reported
that patient counselling prevents adverse drug events
during and after hospitalisation [43].
The study had some limitations. The study evaluated
voluntary incident reports. Voluntary reports could be
underreported and did not provide the actual frequency
of the total denominator of errors that were detected
and ameliorated. Secondly, reports did not contain infor-
mation on whether errors reached patients and the
effects of any harm. Moreover, the study could not
assess the outcomes of the interventions performed by
pharmacist.
Conclusions
Hospital pharmacists identified a lot of drug use chal-
lenges and subsequently prevented errors from reaching
patients. Majority of pharmacist interventions and rec-
ommendations to prevent or ameliorate drug errors
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